Search the Newsreel

Pulse Biosciences Inc (PLSE) Institutional Confidence

Pulse Biosciences Inc (PLSE) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 30.37% quarter-over-quarter, reaching 11.76%. The largest institutional shareholder, Bill Nygren | OAKMX, holds 6.89K shares, …

Pulse Biosciences' Atrial-Fibrillation Study Passes Halfway Mark

$Pulse Biosciences (PLSE.US)$ the squeeze is onnnnnnnnn

The article is a short social media post by user Papacito on the moomoo Community platform, stating that Pulse Biosciences ($PLSE.US$) is "squeeeeezing." The post consists of a single sentence and a featured image, focusing on the potential for a short squeeze in the …

Oppenheimer raises Pulse Biosciences stock price target on AF data

Oppenheimer has increased its price target for Pulse Biosciences (NASDAQ:PLSE) to $35.00 from $30.00, maintaining an Outperform rating, following positive data from the company's nsPFA EFS study on atrial fibrillation. The stock has seen a 142% surge in the past six months and is …

Pulse Biosciences (PLSE) Stock Looks Above Fair Value Today

Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Pulse Biosciences Inc (PLSE), categorizing its revenue by business segments (Systems, Cycle units) and geographical regions (North America, Rest of World). The data presented shows that as of the updated information on Tuesday, January 6, the …

Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pulse Biosciences Inc (PLSE) dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years. The page lists current stock pricing and market capitalization information for PLSE.

Pulse Biosciences Inc (PLSE) Cash Flow

This article provides a detailed historical overview of Pulse Biosciences Inc's (PLSE) cash flow statements, including operating, investing, and financing activities, presented quarterly and annually. It highlights key financial figures such as operating cash flow, net income from continuing operations, capital expenditures, and free …

Pulse Biosciences stock hits 52-week high at 31.09 USD

Pulse Biosciences Inc. reached a new 52-week high of $31.09, driven by significant stock appreciation, positive Q1 2026 financial results where EPS beat expectations, and strategic moves like warrant redemptions. The company also received a "buy" rating and $32 price target from Canaccord Genuity, …

Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month High - Still a Buy?

Pulse Biosciences to report Q2 2026 results on August 6

Pulse Biosciences, Inc. announced it will release its Q2 2026 financial results after market close on August 6, 2026, followed by a conference call at 1:30 PM PT to discuss business updates. The company utilizes its Nanosecond Pulsed Field Ablation (nsPFA) technology and will …

Pulse Biosciences, Inc (PLSE) Stock Analysis: Unpacking The 5.89% Potential Upside

Pulse Biosciences, Inc (PLSE) is a U.S.-based medical instruments and supplies company with a $2 billion market capitalization, specializing in bioelectric medicine through its nPulse System. Despite analysts forecasting a potential 5.89% upside with a target price between $30.00 and $32.00, the company faces …

Pulse Biosciences schedules its next financial update for Aug. 6

PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Pulse Biosciences announced inducement grants to three new employees consistent with Nasdaq Listing Rule 5635(c)(4). These grants, totaling 51,000 stock options and 21,000 restricted stock units, were approved by the Compensation Committee and are intended to align the interests of new hires with those …

Pulse Biosciences' Three New Employees Get $25.89 Options

PLSE Forecast — Price Target — Prediction for 2027

Is Pulse Biosciences (PLSE) Quietly Redefining Its Core Identity Around Atrial Fibrillation?

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences brings one-year AFib data and live case to HRS 2026

Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock

Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited